(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lepareur, Nicolas, Ardisson, Valérie, Noiret, Nicolas, Garin, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299367/
https://www.ncbi.nlm.nih.gov/pubmed/22518301
http://dx.doi.org/10.1155/2012/278306
_version_ 1782226114498789376
author Lepareur, Nicolas
Ardisson, Valérie
Noiret, Nicolas
Garin, Etienne
author_facet Lepareur, Nicolas
Ardisson, Valérie
Noiret, Nicolas
Garin, Etienne
author_sort Lepareur, Nicolas
collection PubMed
description Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.
format Online
Article
Text
id pubmed-3299367
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32993672012-04-19 (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside Lepareur, Nicolas Ardisson, Valérie Noiret, Nicolas Garin, Etienne Int J Mol Imaging Research Article Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described. Hindawi Publishing Corporation 2012 2012-02-22 /pmc/articles/PMC3299367/ /pubmed/22518301 http://dx.doi.org/10.1155/2012/278306 Text en Copyright © 2012 Nicolas Lepareur et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lepareur, Nicolas
Ardisson, Valérie
Noiret, Nicolas
Garin, Etienne
(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title_full (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title_fullStr (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title_full_unstemmed (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title_short (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
title_sort (188)re-sss/lipiodol: development of a potential treatment for hcc from bench to bedside
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299367/
https://www.ncbi.nlm.nih.gov/pubmed/22518301
http://dx.doi.org/10.1155/2012/278306
work_keys_str_mv AT lepareurnicolas 188ressslipiodoldevelopmentofapotentialtreatmentforhccfrombenchtobedside
AT ardissonvalerie 188ressslipiodoldevelopmentofapotentialtreatmentforhccfrombenchtobedside
AT noiretnicolas 188ressslipiodoldevelopmentofapotentialtreatmentforhccfrombenchtobedside
AT garinetienne 188ressslipiodoldevelopmentofapotentialtreatmentforhccfrombenchtobedside

Ejemplares similares